Category: New research findings

My dog Jack and I are diligent about getting our 10,000 steps walking every day.  Many studies have shown that regular exercise reduces the risk of getting dementia including Alzheimer’s, but questions remain: How much...

While doing a genetic genealogical search in 2012, I inadvertently discovered that I have two copies of the APOE-4 allele putting me at very high risk of developing Alzheimer’s dementia. However, as a neurologist,...

Lois, my wife and a retired librarian, got me started keeping track of my book reading using the Goodreads website in 2008. It took me a couple of years to get it right, remembering...

Last February I posted an essay on this blog titled “Hearing loss, aphasia and dementia” about my increasing problem with understanding speech. I suspected that my trouble with speech was due to a combination...

The results of the phase 3 clinical trial of the anti-amyloid monoclonal antibody donanemab were released simultaneously today at the Alzheimer’s Association Clinical Conference (AAIC) in Amsterdam and in a paper published in JAMA....

Two important things happened this week.  On the Fourth of July, my granddaughter Emily got her first ride in a canoe. She was thrilled. The other important thing that happened this week was the FDA...

After years of failed trials, two and possibly three anti-amyloid monoclonal antibodies have shown efficacy at removing beta-amyloid from the brain of subjects with mild Alzheimer’s disease. Two of them, lecanemab and donanemab, have...

There are now two anti-amyloid monoclonal antibodies that appear to be effective in slowing the progression of cognitive impairment in people with mild Alzheimer’s disease. The benefit may be small, 27% for lecanemab and...

Yesterday Eli Lilly issued a press release summarizing positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slows cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab is unique...